BENGALURU (Reuters) – Shares of Indian drug-maker Dr. Reddy’s Laboratories were down 6.5% on Monday after the U.S. Food and Drug Administration issued three observations for the company’s plant in Telangana state.
(Reporting by Varun Vyas in Bengaluru; Editing by Dhanya Ann Thoppil)
Disclaimer: This report is auto generated from the Reuters news service. ThePrint holds no responsibilty for its content.